drugset / Trial / NCT07262814

Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini

NCT07262814

RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.

Timeline

Start
2026-07-20
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject arpraziquantel Small molecule 20 mg/kg Oral
Subject arpraziquantel Small molecule 30 mg/kg Oral
Subject arpraziquantel Small molecule 40 mg/kg Oral
Subject arpraziquantel Small molecule 50 mg/kg Oral
Subject arpraziquantel Small molecule 60 mg/kg Oral

Indications